CAMBRIDGE, England, September 17 /PRNewswire/ --

- Being Launched at TechnoPharm 2008 Exhibition

Capsugel, the world's leading provider of oral dosage form solutions to the pharmaceutical and related healthcare industries, is pleased to announce the release of its new Xcelohood(TM) Containment System. Designed for fully integrated use with the Xcelodose(R) Precision Micro-dosing System, it enables safer containment, particularly when filling capsules with potentially toxic and potent compounds.

LONDON, September 17 /PRNewswire/ --

- UK Brand Managers and Marketers can now Respond to Customers' Online Behaviour in 'Real-Time' by Creating Relevant and Timely Email Content on the Fly

Maxymiser, the online content optimisation specialist, has announced an extension to its existing product portfolio with the launch of its new email optimisation software.

VIENNA, Austria, September 17 /PRNewswire/ -- WestLB AG and VocaLink, the payment transaction specialists, signed a cooperation agreement for processing SEPA payments at the SIBOS international banking fair in Vienna. The agreement paves the way for direct routing of all payments by banks connected to VocaLink in favour of savings banks in Germany and vice-versa. WestLB will utilise the opportunities afforded by VocaLink through its Euro CSM (Clearing & Settlement Mechanism). In return, VocaLink will profit from the networking of WestLB in the Sparkassen-Finanzgruppe. Synergies from the networking ultimately benefit all customers through low-cost and timely processing of their payment transfers.

YAROSLAVL, Russia, September 17 /PRNewswire/ -- TGC-2 (MICEX, RTS: TGKB), the largest heat and power generating company in the Northern part of Russia, releases Annual Report 2007.

Strategic goal of the Company is the investment attractiveness and capitalization growth.

The Company was formed under the decision of its single founder RAO UES of Russia and registered on April 19, 2005 in Yaroslavl.

The formation of the Company's Target Structure was completed on May 3, 2007 through a merger with the six regional generating companies, which were created as a result of reforming AO-energo. The largest shareholders of the Company are KORES INVEST Ltd. and Archivo Limited - 45.35% and 25.95% from voting shares.

FRIMLEY, England, September 17 /PRNewswire/ --

- 82% of patients with pancreatic neuroendocrine tumours (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin(R) LAR(R)(1)

- 77% of patients with pancreatic NET experienced clinical benefit when treated with daily RAD001(1)

- Data show RAD001, an oral mTOR inhibitor, has potential to become new treatment for patients with pancreatic NET who currently have limited options(1)

- Phase III trials underway to confirm impact of combination RAD001 and Sandostatin(R) LAR(R) therapy on survival in pancreatic NET and carcinoid patients

FRIMLEY, England, September 17 /PRNewswire/ --

- New data, updated since ASCO, show time without tumour growth now reaches nearly 5 months with RAD001 vs. 1.9 months with placebo(1)

- One quarter of patients in trial remained progression-free beyond ten months of treatment(1)

- RAD001 is first drug to show significant benefit after failure of initial therapy, Sutent(R) (sunitinib) or Nexavar(R) (sorafenib)**, with potential to address unmet medical need(1)

- RAD001 under review by regulatory authorities; potential to be first once-daily oral mTOR therapy for advanced kidney cancer

New data continue to demonstrate the potential benefit of RAD001 (everolimus) for patients with advanced kidney cancer who have failed standard therapies.

DUBLIN, Ireland and NEWCASTLE, England, September 17 /PRNewswire/ --

- Ovation and Biovail to Market First Treatment Licensed for Movement Disorders Associated With Huntington's Disease

DUBLIN, Ireland and NEWCASTLE, England, September 17 /PRNewswire/ --

Cambridge Laboratories Group Limited ("Cambridge" or the "Company"), the privately-owned specialty pharmaceutical company, announces today that its product XENAZINE(R) (tetrabenazine), the first and only product for the treatment of chorea associated with Huntington's disease, will be marketed in the US by Ovation Pharmaceuticals, Inc. and in Canada by Biovail Corporation (NYSE/TSX: BVF).

WARSAW, September 17 /PRNewswire/ -- TS2 Satellite Technologies (http://www.ts2.pl) has completed the tender documentation for JCC-I/A and a satellite network project for the Marines bases in Afghanistan. The government contract concerns establishing and maintaining full communications in new locations for all soldiers stationed there during next two years. The USA is going to transfer 4.5 thousand Marines from Iraq to Afghanistan as early as at the beginning of 2009.

NEW YORK, September 17 /PRNewswire/ -- GoldenSource Corporation, a global software provider of Enterprise Data Management (EDM) solutions for financial and securities institutions worldwide, today announced the appointment of Massimo Broggi as Sales Manager for Southern Europe and the Middle East.

Based in Milan, Broggi will be responsible for developing and expanding business strategies for GoldenSource in the region with particular emphasis on helping local clients implement data management strategies to manage risk related to derivates operations, counterparty exposure and fragmented reference data. Broggi reports to Hugh Stewart, vice president of sales and marketing, EMEA and Asia.

LONDON, September 17 /PRNewswire/ -- Reducing the cost and complexity of sharing news is a crucial topic of discussion among news providers and web site owners, and there is no better source of advice than an International Press Telecommunications Council (IPTC) seminar.

An important IPTC information session will be held at IFRA Expo 2008 on 29 October in beautiful Amsterdam, and news industry technical leaders are invited to attend.